This inventor holds 1 USPTO granted patent. Top assignee: Cipla Limited. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Nayan Shivalkar: Innovator in Pharmaceutical Chemistry
Introduction
Nayan Shivalkar, based in Thane, India, is a distinguished inventor recognized for his significant contributions to pharmaceutical chemistry. With a unique focus on the separation of diastereomers, Shivalkar has developed innovative processes that improve the efficacy of pharmaceutical compounds.
Latest Patents
Shivalkar holds a patent for an efficient process for the separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine. This invention details a method not only for separating these complex compounds but also for preparing two distinct derivatives of the adenine compound, thereby enhancing its medicinal applications.
Career Highlights
Currently, Nayan Shivalkar is employed at Cipla Limited, a global leader in the pharmaceutical industry. His role involves leveraging his expertise to develop innovative solutions in drug formulation and delivery. His commitment to advancing pharmaceutical sciences has made him a valuable asset to his team.
Collaborations
Throughout his career, Shivalkar has collaborated with several talented professionals, including Dharmaraj Ramachandra Rao and Ashwini Amol Sawant. These partnerships have fostered a collaborative environment that nurtures creativity and innovation, contributing to the advancement of their collective work in pharmaceutical research.
Conclusion
Nayan Shivalkar is a notable figure in the field of pharmaceutical inventions, offering a profound impact through his patent on diastereomer separation. His work continues to inspire advancements in pharmaceutical processes at Cipla Limited, highlighting the importance of innovation in enhancing therapeutic efficacy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
